PT - JOURNAL ARTICLE AU - Monson, Eric T. AU - Colbert, Sarah M. C. AU - Andreassen, Ole A. AU - Ayinde, Olatunde O. AU - Bejan, Cosmin A. AU - Ceja, Zuriel AU - Coon, Hilary AU - DiBlasi, Emily AU - Izotova, Anastasia AU - Kaufman, Erin A. AU - Koromina, Maria AU - Myung, Woojae AU - Nurnberger, John I. AU - Serretti, Alessandro AU - Smoller, Jordan W. AU - Stein, Murray B. AU - Zai, Clement C. AU - , AU - Aslan, Mihaela AU - Barr, Peter B. AU - Bigdeli, Tim B. AU - Harvey, Philip D. AU - Kimbrel, Nathan A. AU - Patel, Pujan R. AU - , AU - Ruderfer, Douglas AU - Docherty, Anna R. AU - Mullins, Niamh AU - Mann, J. John TI - Defining Suicidal Thought and Behavior Phenotypes for Genetic Studies AID - 10.1101/2024.07.27.24311110 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.27.24311110 4099 - http://medrxiv.org/content/early/2024/07/29/2024.07.27.24311110.short 4100 - http://medrxiv.org/content/early/2024/07/29/2024.07.27.24311110.full AB - Background Standardized definitions of suicidality phenotypes, including suicidal ideation (SI), attempt (SA), and death (SD) are a critical step towards improving understanding and comparison of results in suicide research. The complexity of suicidality contributes to heterogeneity in phenotype definitions, impeding evaluation of clinical and genetic risk factors across studies and efforts to combine samples within consortia. Here, we present expert and data-supported recommendations for defining suicidality and control phenotypes to facilitate merging current/legacy samples with definition variability and aid future sample creation.Methods A subgroup of clinician researchers and experts from the Suicide Workgroup of the Psychiatric Genomics Consortium (PGC) reviewed existing PGC definitions for SI, SA, SD, and control groups and generated preliminary consensus guidelines for instrument-derived and international classification of disease (ICD) data. ICD lists were validated in two independent datasets (N = 9,151 and 12,394).Results Recommendations are provided for evaluated instruments for SA and SI, emphasizing selection of lifetime measures phenotype-specific wording. Recommendations are also provided for defining SI and SD from ICD data. As the SA ICD definition is complex, SA code list recommendations were validated against instrument results with sensitivity (range = 15.4% to 80.6%), specificity (range = 67.6% to 97.4%), and positive predictive values (range = 0.59-0.93) reported.Conclusions Best-practice guidelines are presented for the use of existing information to define SI/SA/SD in consortia research. These proposed definitions are expected to facilitate more homogeneous data aggregation for genetic and multisite studies. Future research should involve refinement, improved generalizability, and validation in diverse populations.Competing Interest StatementOle Andreassen: Consultant to Cortechs.ai and Precision-Health.ai, and received speaker's honorarium from Lundbeck, Sunovion, Janssen and Otsuka. Murray Stein: MBS has in the past 3 years received consulting income from Aptinyx, atai Life Sciences, BigHealth, Biogen, Bionomics, Boehringer Ingelheim, Delix Therapeutics, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, Karuna Therapeutics, Lykos Therapeutics, NeuroTrauma Sciences, Otsuka US, PureTech Health, Sage Therapeutics, Seaport Therapeutics, and Roche/Genentech. Dr. Stein has stock options in Oxeia Biopharmaceuticals and EpiVario. He has been paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry). He is on the scientific advisory board of the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America. Philip Harvey: Dr. Harvey consults for a variety of pharmaceutical and device manufacturers on phase 2 and 3 studies of cognition and negative symptoms in SMI. These activities have been reviewed and determined not to be related to the content of this paper. John Mann: Dr. Mann receives royalties for commercial use of the C-SSR S from the Research Foundation of Mental Hygiene and from Columbia University for the Columbia Pathways App. All other listed authors declare no conflicts of interest. Funding StatementThis work was funded by NIMH R01MH124839 (Mullins), NIMH R01MH132733 (Ruderfer), R01MH123619 (Docherty), R01MH123489 (Coon), Brain and Behavior Research Foundation (NARSAD Young investigator award No. 31248 to E.M.), and the Huntsman Mental Health Institute. This work was also supported by significant funding that has been provided to the Psychiatric Genomics Consortium from the National Institute of Mental Health (PGC3: U01 MH109528; PGC2: U01 MH094421; PGC1: U01 MH085520). This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. 1842169. JWS was supported in part by R01 MH118233 and MH117599. None of the listed authors or their institutions ate any time received payment or services from a thrid party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data were handled in accordance with oversight and given ethical approval from the Vanderbilt University Medical Center and Veterans Affairs Central Institutional Review Boards.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.